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GATA2 has been well-characterized as a critical pioneer transcription factor for androgen receptor (AR)
in prostate cancer. In this issue of Cancer Cell, Vidal and colleagues identify increased GATA2 and its AR-
independent transactivation of IGF2 as a mechanism that can mediate taxane resistance through activation
of IGF1/insulin receptor signaling.The standard treatment for metastatic
prostate cancer (PCa) is suppression of
testicular androgen synthesis (androgen
deprivation therapy [ADT]) by surgical or
medical castration, but most men relapse
within 2–3 years despite castrate and-
rogen levels (castration-resistant prostate
cancer [CRPC]). It is now clear that
androgen receptor (AR) transcriptional
activity generally persists in CRPC and
that a major driver of this activity is resid-
ual weak androgens produced by the ad-
renal glands that are converted by tumor
cells into testosterone and dihydrotestos-
terone. This residual androgen synthesis
can be markedly suppressed by inhibitors
of the enzyme CYP17A1 such as abirater-
one, and AR activity in CRPC may also be
repressed by the direct AR antagonist en-
zalutamide. Abiraterone and enzaluta-
mide are both now approved for use in
CRPC prior to chemotherapy, but most
patients who respond to either agent re-
lapse within 1–2 years.
A subset of these AR-targeted therapy-
resistant tumors may be AR-independent,
but high level AR expression, further AR
gene amplification, and certain AR-acti-
vating mutations indicate that AR activity
still generally persists and contributes to
growth. AR in these tumors also may be
sensitized to low levels of androgens by
diverse mechanisms, including increased
expression of FOXA1 and GATA2, which
both function as pioneer transcription fac-
tors to establish and maintain open chro-
matin at AR regulated enhancers and to
increase AR binding and activity at these
sites (Wang et al., 2007; Wu et al., 2014).
Constitutively active AR splice variants
lacking the C-terminal ligand-binding158 Cancer Cell 27, February 9, 2015 ª2015domain are also emerging as a mecha-
nism that can drive AR activity in these
tumors.
Patients who become resistant to AR-
targeted therapies may respond to do-
cetaxel, which functions by binding to
b-tubulin and stabilizing microtubules,
thereby causing mitotic arrest and apo-
ptosis. Docetaxel may also disrupt micro-
tubule-dependent nuclear translocation
of AR and some AR splice variants. Inter-
estingly, patients with intrinsic or acquired
docetaxel resistance may respond to a
related taxane, cabazitaxel, although the
basis for these responses is unclear. Re-
ported mechanisms of taxane resistance
include increased drug efflux by ABC
transporters, mutations or alterations in
b-tubulin isoforms, alterations in microtu-
bule associated proteins, increased ex-
pression of anti-apoptotic proteins, and
bypass of mitotic arrest. However, des-
pite the efficacy of taxanes in PCa, the
role of these or other mechanisms in tax-
ane resistance is poorly understood.
In a previous study using docetaxel-
resistant CRPC cell lines (DU145 and
CWR22Rv1), Domingo-Domenech et al.
(2012) identified Notch- and Hedgehog-
dependent tumor-initiating cells as medi-
ating taxane resistance. In this issue of
Cancer Cell, Vidal et al. (2015) have
derived a docetaxel resistance gene ex-
pression signature from these models
and identified 13 genes in this set that
were also consistently deregulated in
two advanced therapy-resistant PCa da-
tasets. GATA2 was among these genes,
and by IHC they confirmed that GATA2
was increased during progression from
primary PCa to disseminated CRPC andElsevier Inc.found the highest levels in taxane-treated
tumors. They then showed that GATA2
knockdown could resensitize the resistant
DU145 and CWR22Rv1 cells to taxanes
and impair their ability to form xenografts
and extended these findings to two pa-
tient-derived PCa xenografts. Transcrip-
tome profiling after GATA2 knockdown
in the docetaxel-resistant DU145 and
CWR22Rv1 cells (and in a third AR-nega-
tive PCa line, ARCaPM) yielded a signa-
ture of 28 GATA2-regulated genes, which
was also enriched in advanced PCa
clinical datasets. Significantly, as DU145
and ARCaPM cells do not express AR,
this gene set does not include the large
number of genes coregulated by AR and
GATA2 in AR-positive PCa cells (Wang
et al., 2007). Functional studies in the
cell lines distilled this list to 4 GATA2 stim-
ulated genes, IGF2, PAK4, POM121, and
FOXM1. Focusing on IGF2, they then
showed that the effects of GATA2 knock-
down could be significantly rescued by
IGF2 transfections or by addition of re-
combinant IGF2 protein to the medium.
Identification and functional validation of
GATA2 binding sites in one of the IGF2
promoters indicates that GATA2 directly
regulates IGF2. Finally, by IHC the authors
found that IGF2, similarly to GATA2,
was increased with PCa progression to
CRPC and taxane resistance.
IGF2 is a ligand for the IGF 1 receptor
(IGF1R), has high affinity for an alternative
short isoform (isoform A) of the insulin
receptor (INSR), and can also activate
certain IGF1R:INSR hybrid receptors.
Consistent with these functions, IGF2
knockdown in taxane-resistant PCa cells
caused decreased phosphorylation of
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pathway activity as evidenced by dec-
reased AKT phosphorylation, decreased
JNK phosphorylation, and (only in
DU145) decreased ERK1/2 phosphoryla-
tion. Moreover, combined treatment with
a PI3K or AKT inhibitor, in conjunction
with a JNK inhibitor, strongly diminished
taxane resistance, indicating that IGF2
is mediating resistance through these
pathways. As expected based on the
anti-apoptotic activities of the PI3K and
MAPK pathways, increased IGF2 and tax-
ane resistance were associated with
resistance to other apoptotic stimuli in-
cluding radiation and oxidative stress.
Finally, in preclinical xenograft models,
the authors showed that treatment with
a dual IGF1R/INSR small molecule inhi-
bitor currently in clinical trials (OSI-906,
linsitinib) could restore sensitivity to doce-
taxel and cabazitaxel.
Together, these results have identified
GATA2-driven IGF2 production as an
AR-independent function of GATA2 that
can mediate resistance to taxanes and
other apoptotic stimuli and suggest that
increased GAT2 may contribute to the
relative cross-resistance between taxane
and androgen deprivation therapies
(Cheng et al., 2015). Previous preclinical
trials have similarly suggested that
IGF1R inhibition would provide clinical
benefit as an adjunct to castration and
would further enhance docetaxel treat-
ment (Wu et al., 2006). However, despite
the provocative clinical associations, pre-
clinical data in this study, and previous
data linking increased IGF signaling to
PCa progression, the physiological signif-
icance and therapeutic potential of target-
ing this mechanism remain to be estab-
lished. The critical role of GATA2 for AR
function is one confounding factor,
because increased GATA2 in clinicalsamples may also be driven by selective
pressure to maintain AR activity. More
importantly, while IGF2 mediated IGF1R/
INSR stimulation appears to be the major
driver of the PI3K and JNK pathways in
the models in this study, many additional
stimuli (such as the frequent loss of
PTEN) may activate these pathways in
advanced PCa. Finally, PCa clinical trials
of agents targeting IGF signaling have
not yet shown clear efficacy. These
include a trial of ADT combined with cixu-
tumumab (anti-IGF1R antibody) in meta-
static hormone-sensitive PCa (SWOG
S0925, 2014, J Clin Oncol., abstract
5006), and a trial of figitumumab (anti-
IGF1R antibody) plus docetaxel in CRPC
(de Bono et al., 2014).
Nonetheless, while the antibodies in
these previous trials block IGF1R, IGF2
may also be driving proliferation through
the alternative short isoform of the INSR
(isoform A), which is aberrantly expressed
in PCa and other cancers (Heni et al.,
2012). Indeed, a neoadjuvant trial of cixu-
tumumab plus androgen deprivation
found a marked increase in IGF2 with the
potential to activate the INSR isoform A
(Dean et al., 2013). Additionally, previous
trials have not selected for patients based
on features such as increased IGF2, or
possibly intact PTEN, that may indicate a
critical role for IGF signaling. Therefore,
the results of this study should catalyze
the further development of IGF-targeted
clinical trials, including therapies targeting
INSR isoform A, in well-selected PCa
patients. These might include OSI-906 or
other agents inhibiting IGF1 and IGF2
in preclinical development (Friedbichler
et al., 2014). Moreover, these studies
should include careful analyses of tumors
toassess IGF1Rand INSR isoformexpres-
sion and effects of the agents on down-
stream signal transduction pathways.Cancer Cell 27ACKNOWLEDGMENTS
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